PA8779101A1 - "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales" - Google Patents
"compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"Info
- Publication number
- PA8779101A1 PA8779101A1 PA20088779101A PA8779101A PA8779101A1 PA 8779101 A1 PA8779101 A1 PA 8779101A1 PA 20088779101 A PA20088779101 A PA 20088779101A PA 8779101 A PA8779101 A PA 8779101A PA 8779101 A1 PA8779101 A1 PA 8779101A1
- Authority
- PA
- Panama
- Prior art keywords
- metaloproteinases
- marriage
- inhibitors
- tricyclic compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 abstract 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92756307P | 2007-05-04 | 2007-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8779101A1 true PA8779101A1 (es) | 2008-12-18 |
Family
ID=39944224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20088779101A PA8779101A1 (es) | 2007-05-04 | 2008-04-30 | "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales" |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100227859A1 (enExample) |
| EP (1) | EP2144893A2 (enExample) |
| JP (1) | JP2010526106A (enExample) |
| AR (1) | AR066412A1 (enExample) |
| CA (1) | CA2685389A1 (enExample) |
| CL (1) | CL2008001257A1 (enExample) |
| MX (1) | MX2009011749A (enExample) |
| PA (1) | PA8779101A1 (enExample) |
| PE (1) | PE20090223A1 (enExample) |
| TW (1) | TW200900397A (enExample) |
| WO (1) | WO2008137816A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1987034B1 (en) * | 2006-02-22 | 2011-07-20 | Vertex Pharmceuticals Incorporated | Spiro condensed piperidines as modulators of muscarinic receptors |
| WO2010091185A2 (en) * | 2009-02-05 | 2010-08-12 | Trustees Of Boston College | Inhibitors of fructose 1,6-bisphosphatase and methods of use thereof |
| NZ596144A (en) * | 2009-04-06 | 2014-01-31 | Ptc Therapeutics Inc | Indole derivatives and methods for antiviral treatment |
| US10377734B2 (en) | 2013-02-08 | 2019-08-13 | Mitsubishi Gas Chemical Company, Inc. | Resist composition, method for forming resist pattern, polyphenol derivative for use in the composition |
| JP6401773B2 (ja) | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| JP7026439B2 (ja) | 2014-12-25 | 2022-02-28 | 三菱瓦斯化学株式会社 | 化合物、樹脂、リソグラフィー用下層膜形成材料、リソグラフィー用下層膜、パターン形成方法及び精製方法 |
| US11480877B2 (en) | 2015-03-31 | 2022-10-25 | Mitsubishi Gas Chemical Company, Inc. | Resist composition, method for forming resist pattern, and polyphenol compound used therein |
| JP6845991B2 (ja) * | 2015-03-31 | 2021-03-24 | 三菱瓦斯化学株式会社 | 化合物、レジスト組成物及びそれを用いるレジストパターン形成方法 |
| EP3346335A4 (en) | 2015-08-31 | 2019-06-26 | Mitsubishi Gas Chemical Company, Inc. | MATERIAL FOR FORMING LITHOGRAPHY OF LAYER LAYERS, COMPOSITION FOR FORMING LITHOGRAPHY LAYER LAYERS, LITHOGRAPHY LAYERINGS AND METHOD FOR THE PRODUCTION THEREOF, PATTERN FORMULATION, RESIN AND CLEANING METHOD |
| EP3346334B1 (en) | 2015-08-31 | 2020-08-12 | Mitsubishi Gas Chemical Company, Inc. | Use of a composition for forming a photoresist underlayer film for lithography, photoresist underlayer film for lithography and method for producing same, and resist pattern forming method |
| CN108137478B (zh) | 2015-09-10 | 2021-09-28 | 三菱瓦斯化学株式会社 | 化合物、其组合物、纯化方法以及抗蚀图案形成方法、非晶膜的制造方法 |
| US10042251B2 (en) | 2016-09-30 | 2018-08-07 | Rohm And Haas Electronic Materials Llc | Zwitterionic photo-destroyable quenchers |
| GB201617339D0 (en) | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| KR102435507B1 (ko) * | 2019-07-31 | 2022-08-24 | 일동제약(주) | 신규 벤조퓨란 유도체 및 이의 용도 |
| CN113929645B (zh) * | 2021-12-15 | 2022-03-11 | 长沙普济生物科技股份有限公司 | 一种光催化合成苯并呋喃基氨基酸表面活性剂的方法 |
| CN117045635A (zh) * | 2022-05-13 | 2023-11-14 | 中国海洋大学 | 一种3-苯基二苯并呋喃类化合物在药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2256631A1 (en) * | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Compounds for and a method of inhibiting matrix metalloproteinases |
| KR20000068414A (ko) * | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도 |
| TR200202164T2 (tr) * | 1999-08-18 | 2002-11-21 | Warner-Lambert Company | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. |
| MXPA01013172A (es) * | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US20030157110A1 (en) * | 2002-01-07 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
| JP2010507674A (ja) * | 2006-10-27 | 2010-03-11 | ワイス エルエルシー | マトリクスメタロプロテアーゼ阻害剤としての三環式化合物 |
-
2008
- 2008-04-30 PE PE2008000773A patent/PE20090223A1/es not_active Application Discontinuation
- 2008-04-30 CL CL200801257A patent/CL2008001257A1/es unknown
- 2008-04-30 AR ARP080101855A patent/AR066412A1/es unknown
- 2008-04-30 PA PA20088779101A patent/PA8779101A1/es unknown
- 2008-05-05 EP EP08755041A patent/EP2144893A2/en not_active Withdrawn
- 2008-05-05 JP JP2010506709A patent/JP2010526106A/ja not_active Withdrawn
- 2008-05-05 CA CA002685389A patent/CA2685389A1/en not_active Abandoned
- 2008-05-05 TW TW097116522A patent/TW200900397A/zh unknown
- 2008-05-05 US US12/598,868 patent/US20100227859A1/en not_active Abandoned
- 2008-05-05 MX MX2009011749A patent/MX2009011749A/es not_active Application Discontinuation
- 2008-05-05 WO PCT/US2008/062593 patent/WO2008137816A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001257A1 (es) | 2008-07-04 |
| MX2009011749A (es) | 2009-11-11 |
| WO2008137816A2 (en) | 2008-11-13 |
| WO2008137816A3 (en) | 2009-05-14 |
| US20100227859A1 (en) | 2010-09-09 |
| CA2685389A1 (en) | 2008-11-13 |
| TW200900397A (en) | 2009-01-01 |
| AR066412A1 (es) | 2009-08-19 |
| EP2144893A2 (en) | 2010-01-20 |
| JP2010526106A (ja) | 2010-07-29 |
| WO2008137816A8 (en) | 2010-01-28 |
| PE20090223A1 (es) | 2009-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010129A (es) | Inhibidores de quinasas símil polo | |
| CO6541606A2 (es) | Espiroindolinona- pirrolidinas | |
| MX2019010602A (es) | Inhibidores de cdk. | |
| CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| ECSP11010889A (es) | INHIBIDORES DE cMET | |
| BR112013027500A2 (pt) | liberação controlada de imunossupressores de nanotransportadores sintéticos | |
| UY32723A (es) | Compuestos de triazol que portan un sustituyente de azufre x | |
| CL2012000059A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras. | |
| CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
| HN2012000263A (es) | Derivados n1-sulfonil-5-fluoropirimidinona | |
| SV2011003855A (es) | Heteroarilos sustituidos | |
| UY32631A (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparación y su aplicación en terapéutica. | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
| MX377553B (es) | Composicion farmaceutica estable y metodos de uso de la misma. | |
| UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
| UY32630A (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica. | |
| CO6361910A2 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
| ECSP10010688A (es) | Activadores de glucoquinasa | |
| UY34388A (es) | "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS" | |
| BR112015005862A2 (pt) | derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase | |
| UY32704A (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| UY32077A (es) | Inhibidores de quinasa tipo polo |